Key result
Pravastatin administration in pregnant women with severe preeclampsia and intrauterine growth restriction prolonged the median time from diagnosis to delivery to 39 days compared to 20 days in controls.
Why the study?
Recent literature highlighted pravastatin's potential in preventing and treating preeclampsia and IUGR, but perinatal outcomes and placental findings needed description.
Does pravastatin improve perinatal outcomes and placental histopathology in pregnant women with severe preeclampsia and intrauterine growth restriction?
Cohort
No
Does pravastatin improve perinatal outcomes and placental histopathology in pregnant women with severe preeclampsia and intrauterine growth restriction?
Absolute Event Rate: 39% vs 20%
Pravastatin administered in the late second trimester for severe preeclampsia with IUGR may prolong pregnancy and increase prenatal weight gain, though it did not significantly alter placental histopathology or 2-year infant outcomes.
No takes yet. Share an insight, caveat, or question.
May prolong gestation in severe preeclampsia with IUGR; leaves open confirmation in randomized trials.
Fruci et al. (2023) conducted a cohort in Severe preeclampsia and intrauterine growth restriction. Pravastatin vs. Controls with similar gestational age, clinical maternal data, and Doppler severity findings was evaluated on Median time from diagnosis to delivery (days). Pravastatin administration in pregnant women with severe preeclampsia and intrauterine growth restriction prolonged the median time from diagnosis to delivery to 39 days compared to 20 days in controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: